Abstract:Objective The purpose of this study was to investigate the optimal initial dose of levothyroxine(L-T_4)for treatment of congenital hypothyroidism(CH).Methods One hundred and twenty-seven CH infants were assigned to A(n=36),B(n=51),and C(n=40)groups.Different initial doses were given to the patients,10 μg·kg~(-1)·d~(-1) for A group,8 μg·kg~(-1)·d~(-1) for B group and 6 μg·kg~(-1)·d~(-1) for C group.Blood TSH,L and FT_4 Ievels were determined at 2 weeks,4-6 weeks and 8-12 weeks after medication.L-T_4 dose was adiusted individually according to the blood hormone levels.Thyroid hormone levels were rechecked every three months after 12 weeks of medication.All the patients were followed up for 2 years,with regular assessment of growth,development,and thyroid ultrasonography.Results After 2 weeks'medication,TSH levels in both A and B groups were reduced to reference range[(1.3±1.5)mU/L and(3.7±5.6)mU/L].No difference was found between the 2 groups(P=0.28).Eight patients(22.2%)in the A group had a reduced TSH level to less than0.5 mU/L.TSH level in the C group remained abnormal[(11.4±16.5)mU/L]and significant difierence was observed when compared with those in the B and C groups(P<0.01).10 patients in the C group had a TSH level more than 10 mU/L[(34.0±19.2)mU/L].T_4 and FT_4 levels in all the three groups increased markedly.9patients(25.0%)in the A group had T_4 level more than 250 nmol/L,and 11 patients(30.6%)showed hyperthyroxinemia with FT_4 level more than 45 pmol/L(1.5 folds of upper limit of the reference range).13patients in the A group showed clinical symptoms of hyperthyroidism such as diarrhea,irritability,sweating,cry,and so on.After 12 weeks medication,no significant difference was found in blood TSH,T_4,and FT_4 levels among the 3 groups.Also no difference was observed in adjusted L-T_4 dosages among the 3 groups.After 2-year follow-up,clinical examinations including height,weight,bone age,and mental development were all normal for the patients.No differences were found among the 3 groups(all P>0.05).Conclusions Optimal initial dosage of L-T_4 for CH treatment in our country is(8.0±0.5)μg·kg~(-1)·d~(-1) which is proved to be safe and effective.L-T_4dosage should be individualized.To maintain the thyroid function in the age-matched normal reference will lead to normal growth and development.

Association of pharmacogenomic, clinical and behavioural factors with oral levothyroxine (LT-4) dose of hypothyroid patients in Sri Lanka: a matched case control study

Low initial dose of levothyroxine for treatment of congenital hypothyroidism]

Analysis of factors influencing the dose of levothyroxine treatment in adequately controlled hypothyroid patients of different etiologies

Analysis of dose–TSH response effect of levothyroxine soft-gel formulation

Adequate Dose of Levothyroxine for Thyroid-Stimulating Hormone Suppression after Total Thyroidectomy in Patients with Differentiated Thyroid Cancer

Optimizing Levothyroxine Replacement: A Precision Dosage Model for Post-Thyroidectomy Patients

Levothyroxine Therapy in Thyrodectomized Patients

Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia

LEVOTHYROXINE REPLACEMENT IN OBESE HYPOTHYROID FEMALES AFTER TOTAL THYROIDECTOMY

Alternative routes of levothyroxine administration for hypothyroidism

A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism

Identifying Predictors of Prolonged Levothyroxine Dose Adjustment After Thyroidectomy

Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease

Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism

Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy

Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey

Screening factors affecting proper levothyroxine therapy among patients with primary hypothyroidism: a cross-sectional study

Clinical inertia in thyrotropin suppressive therapy for low-risk differentiated thyroid cancer: A real-world experience at an endocrine center in Bangkok

Optimal Initial Dose of Levothyroxine for Treatment of Congenital Hypothyroidism

Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?

Thyroid Hormone Replacement Dosing after Bariatric Surgery in Patients with Primary Hypothyroidism And Severe Obesity: Tehran Obesity Treatment Study